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Abstract
Context
Patients with adrenal incidentalomas (AI) may experience detrimental consequences due
to a minimal cortisol excess sustained by adrenal adenoma. SNPs of the glucocorticoid
receptor gene (NR3C1) modulate individual sensitivity to glucocorticoids and may interfere
with the clinical presentation.
Objective
To compare the frequency of N363S, ER22/23EK and BclI SNPs in patients with AI with the
general population and to evaluate whether these SNPs are linked to consequences of cor-
tisol excess.
Setting
Multicentric, retrospective analysis of patients referred from 2010 to 2014 to 4 centers
(Orbassano, Milano, Messina [Italy] and Zagreb [Croatia]).
Patients
411 patients with AI; 153 males and 258 females and 186 from blood donors.
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Main outcomesmeasures
All patients and controls were genotyped for BclI, N363S and ER22/23EK and SNPs fre-
quency was associated with clinical and hormonal features.
Results
SNP frequency was: SNP frequency was: N363S 5.4% (MAF 0.027), BclI 54.7% (MAF
0.328), ER22/23EK 4.4% (MAF 0.022), without any significant difference between patients
and controls. N363S was more frequent in hypertensive patients (p = 0.03) and was associ-
ated with hypertension (p = 0.015) in patients with suppressed cortisol after the 1-mgDST.
Conclusions
Our results demonstrate that SNPs of the glucocorticoid receptor gene do not play a patho-
genetic role for AI. The impact of any single SNP on the phenotypic expression of minimal
cortisol excess is limited and their analysis does not provide additional data that may be
exploited for patient management.
Introduction
Several glucocorticoid receptor (GR) gene polymorphisms have been described that may play a
crucial role for glucocorticoidaction, influencing glucocorticoid sensitivity and conferring a
potential susceptibility to a variety of diseases, such as osteoporosis [1] or metabolic disorders
[2, 3]. However, different GR single nucleotide polymorphisms (SNPs) show varying func-
tional significance. The BclI and the N363S SNPs have been associated in the general popula-
tion with enhanced glucocorticoid sensitivity and, consequently, with increased abdominal fat
mass, higher cholesterol levels, hyperinsulinemia, and low bonemineral density [4, 5, 6, 7]. In
contrast, the ER22/23EKGR SNP is associated with relative GC resistance that may confer to
carriers favorable metabolic parameters and body composition [3, 8].
Investigation of GR gene SNPs in patients with Cushing’s syndrome has shown a higher fre-
quency of BclI compared with healthy controls, while no significant differences were found in
the frequency of the other SNPs. Despite the significantly increased levels of morning serum
cortisol in the BclI carriers, no clinical or metabolic differences were found between these
patients and wild type carriers [9]. In another study, patients with Cushing’s syndrome with
the BclI SNP had reduced femoral bone mineral density compared to patients with wild type
GR[1].
In patients with Addison’s disease, Giordano at al. found that BclI may contribute to
increased central adiposity, impaired glucosemetabolism and dyslipidaemia [10]. Another
study suggests that the homozygous BclI genotype (GG) may be associated with higher bone
resorption in adult with primary adrenal insufficiency. Moreover, GG carriers needed lower
hydrocortisone replacement doses supporting the view that this GR SNP is associated with
increased cortisol sensitivity[11].
Patients with adrenal incidentalomas are an interesting cohort to study GR SNPs, since 5%
to 30% of such patients may show mild cortisol excess without specific Cushingoid signs [12,
13]. However, chronic exposure to an evenminimal cortisol excess is not exempt of detrimen-
tal consequences. Evidence is gathering that this condition portends an increased risk of car-
diovascular events and an impaired bone health with high fracture risk [14,15]. Thus, it is
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tempting to speculate that the individual sensitivity to glucocorticoidsmay play a role to influ-
ence development of the classic complications of cortisol excess in patients exposed to slightly
elevated cortisol levels.
The aims of the present study were to assess whether the prevalence of N363S, ER22/23EK
and BclI SNPs is different in patients with adrenal incidentalomas compared to the general
population, and to evaluate whether these SNPs may be linked to any hormonal or metabolic
abnormalities that confer an increased cardiovascular risk in patients with adrenal
incidentalomas.
Patients andMethods
Study subjects
We did a retrospective evaluation of 411 patients (median age 62 years, range 33–86 years).
They were 153 male (median age 63 years, range 35–86 years) and 258 female (median age 61
years, range 33–84 years) subjects, who were drawn from a series of consecutive patients with
adrenal incidentalomas referred to four centres partaking in the European Network for the
Study of Adrenal Tumours from 2010 to 2014 (Orbassano, Milano, Messina [Italy] and Zagreb
[Croatia]).
In agreement with the definition of adrenal incidentaloma (adrenal mass detected unexpect-
edly by imaging procedures performed for reasons unrelated to adrenal diseases) [12] patients
with severe or resistant hypertension, or paroxysmal hypertension, or hypokaliemia, or clinical
signs of hypercortisolism (facial plethora, striae rubrae, easy bruising, proximal muscle weak-
ness) were excluded. Patients with known extra-adrenal malignancies were also excluded from
the study. From the overall series of adrenal incidentalomas, only the patients with a presumed
cortical adenoma were selected for the study.
Diagnosis of adrenal adenoma was based on the following CT features: size less than 6 cm,
regular mass shape with well-definedmargins, and homogeneous enhancement with attenua-
tion value less than 10 Hounsfield Units on unenhancedCT [12, 16, 17]. In all patients, CT was
repeated after 3 to 6 months to document unchanged CT features. Catecholamine excess and
primary aldosteronism were excluded in all patients by measuring urinary fractionatedmeta-
nephrines, and by paired evaluation of PRA and plasma aldosterone concentration. A group of
186 healthy volunteers (median age 60 years, range 35–82 years) recruited from blood donors
served as controls. The study was performed according to the Helsinki Declaration II with writ-
ten informed consent obtained from all subjects and approved by the Local Ethics Committees
of the San Luigi Gonzaga Hospital.
For all subjects, weight, height, BMI, systolic blood pressure (SBP), and diastolic blood pres-
sure (DBP) were evaluated. A BMI above 30 kg/m2 was considered as an index of obesity [18].
The waist was measured as the minimum abdominal circumference between the xiphoid pro-
cess and the umbilicus; waist conference above 88 cm in women and 102 cm in men defined
central obesity [19, 20]. According to the ESH and ESC 2013 guidelines [21], blood pressure
was measured in the non-dominant arm, with subjects in a relax sitting position, using a mer-
cury sphygmomanometer placed at the heart level; the average of three measurements was cal-
culated. Hypertension was diagnosedwhen SBP values were>140 mmHg and/or DBP values
>90 mmHg, or whether anti-hypertensive treatment was instituted. Diabetes mellitus was
diagnosedwhen fasting blood glucose levels were 7 mmol/L or greater in two consecutive
determinations or at least 11.1 mmol/L 2h after an oral glucose load [22, 23] or in patients on
insulin or hypoglycemic agents. Hypertriglyceridemiawas diagnosedwhen triglyceride levels
were above 1.69 mmol/L, whereas hypercholesterolemia was diagnosedwhen LDL cholesterol
SNPs of GCReceptorGene in Adrenal Incidentaloma
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levels were above 4.13 mmol/L, and low HDL cholesterol levels were below 1.03 mmol/L [19,
20].
Biochemical tests
Fasting glucose, triglycerides, and total, LDL, HDL cholesterol were measured by standard
procedures.
All patients underwentmeasurements of morning ACTH, 24 -h urinary free cortisol (UFC)
and serum cortisol after overnight 1 -mg dexamethasone suppression test (DST). Premeno-
pausal women were studied in the early follicular phase of the menstrual cycle. Post-DST corti-
sol levels were used to stratify patients in three groups: group 1, patients with complete
suppression (cortisol1.8 μg/dL, 50 nmol/L); group 2, patients with incomplete suppression
(cortisol between 1.9 μg/dL and 3.0 μg/dL [52–83 nmol/L]); group 3, patients with overtly inad-
equate suppression (cortisol>3.0 μg/dL [83 nmol/L]). Hormonal variables were measured in a
single laboratory for each center using commercially available reagents. All samples for an indi-
vidual subject were determined in a single assay in duplicate. Intra- and inter-assay coefficients
of variation for all hormone variables were less than 8% and 12%, respectively.
SNP analysis
All patients and controls were genotyped for the presence of BclI, N363S and ER22/23EK
SNPs.
Total genomic DNA was isolated from 400 μL peripheral blood collected in EDTA tubes
using the automatic extractor “Maxwell”(Promega Corporation,Madison,WI, USA). The
NR3C1 gene SNPs were studied by a pyrosequencing assay (Qiagen, Hilden, Germany): BclI
(rs41423247), N363S (rs56149945) and ER22/23EK (rs6189 and rs6190) as described in Gior-
dano et al. [10] on a PyroMark Q96MA apparatus (Qiagen, Hilden, Germany). Primers and
amplification condition are listed in Table 1.
Statistical Analysis
Continuous data were expressed as mean, standard deviation and interquartile range, while
categorical variables were given as counts and percentages. Comparison between groups was
made using the Mann-Whitney U test for continuous variables and the χ2 test for categorical
variables.
For each SNP, the association with the evaluated variables was performed by logistic regres-
sion models adjusting for potential confounders. Statistical backward selection procedure was
applied to retain in the model all relevant variables that significantly improved the goodness of
fit on the basis of the Akaike Information Criterion (AIC). Interaction among variables was
tested by theWald’s χ2 test. The Firth’s correctionwas applied to reduce bias in the estimates,
Table 1. PCR and pyrosecquencingprimer.
NR3C1 SNPs Forward Primer Reverse Primer Pyrosequencing Primer TA PCR Amplicon lenght
ER23/23EK Bio 5’-GAAGAAAACCCCAGCAGTGTG -3’ 5’-GACGCAGAAACCTTCACAGTAGCT-3’ 5’-GGTTTTATAGAAGTCCATCA-3’ 61°C 98bp
N363S 5’- ACAGCAGGATCAGAAGCCTATTT-3’ Bio 5’-AGTTCAGAGTCCCCAGAGAAGTC-3’ 5’- CCGTTGGTTCCGAAA-3’ 57°C 119bp
BclI 5’- AGGTCTTGCTCACAGGGTTCTTG-3’ Bio 5’- GAACTTGCAGGAACATTTGAACG -3’ 5’- AAGTAGACAAGTTATGTCTG -3’ 58°C 128bp
Bio: the 5’ biotin modification of the PCR primer is required for the DNA single strand DNA capture in the Pyrosequencing assay protocol.
TA: annealing temperature for Polimerase Chain Reaction
doi:10.1371/journal.pone.0162437.t001
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due to the small number of events [24]. Statistical analyses were carried out using R version
3.0.2 [25]. Levels of statistical significancewere set at p less than 0.05.
Results
In the overall series, 65.2% of patients had hypertension, 75.4% were obese, 28.4% had diabetes
and 44.8% had an altered lipid profile. The patients with a normal post-dexamethasone sup-
pression were 55.7%, while 21.9% had cortisol after DST higher than 3 μg/dL (83 nmol/L) and
22.4% of patients had post-dexamethasone cortisol levels between 1.9 μg/dL and 3.0 μg/dL
(52–83 nmol/L). The clinical and biochemical characteristics of the patients are reported in
Table 2.
The allelic frequencies of the BclI, N363S and ER22/23EK SNPs were in Hardy-Weinberg
equilibrium. The carrier frequency for the three variants in patients with AI were as follows,
N363S 5.4% (MAF 0.027), BclI 54.7% (MAF 0.328), ER22/23EK 4.4% (MAF 0.022). We did
not observe any significant difference between patients and controls as to the SNP carrier fre-
quency (5.4% vs 9.1% (MAF 0.046) for N363S, p = 0.1, 54.7% vs 55.4% (MAF 0.309) for BclI,
p = 0.9 and 4.4% vs 3.8% (MAF 0.019) for ER22/23EK, p = 0.7). Italian (n = 310) and Croatian
(n = 101) AI patients were comparable either as carrier frequencies (4.5% vs 7.9% for N363S,
p = 0.2, 53.2% vs 59.4% for BclI, p = 0.3 and 3.9% vs 5.9% for ER22/23EK, p = 0.4) or as MAF
(0.023 vs 0.04 for N363S, p = 0.4, 0.318 vs 0.361 for BclI, p = 0.4 and 0.019 vs 0.03 for ER22/
23EK, p = 0.5). The same was true when patients were stratified for cortisol levels after DST
(Table 2). We have not observed any significant difference between our data and the available
frequency in the European population (p = 0.3 vs EUR, p = 0.7 vs EA and p = 0.7 vs NFE for
N363S, p = 0.07 vs EUR for BclI, p = 0.4 vs EUR, p = 0.4 vs EA and p = 0.7 vs NFE for ER22/
23EK) (Table 3).
Table 2. Clinical and biochemical characteristics and allelic frequencyof the patientswith adrenal incidentalomas categorized for cortisolsecre-
tion after the 1 mgDST.
Group 1 Group 2 Group 3
N = 229 N = 92 N = 90
Age (years) 59.7 ± 10.1 65.1 ± 8.6 63.2 ± 9.5 1 vs 2, p<0.001; 1 vs 3, p = 0.005; 2 vs 3, p = 0.15
Sex (%women) 64.9 60.3 66.7 1 vs 2, p = 0.4; 1 vs 3, p = 0.7; 2 vs 3, p = 0.4
BMI >25 Kg/m2 (%) 79.1 73.2 72.7 1 vs 2, p = 0.2; 1 vs 3, p = 0.2; 2 vs 3, p = 0.9
Elevated waist (%) 55.5 50.0 51.3 1 vs 2, p = 0.4; 1 vs 3, p = 0.5; 2 vs 3, p = 0.9
Hypertension (%) 59.7 69.0 72.8 1 vs 2, p = 0.1; 1 vs 3, p = 0.03; 2 vs 3, p = 0.6
Diabetes (%) 24.0 28.4 36.6 1 vs 2, p = 0.4; 1 vs 3, p = 0.02; 2 vs 3, p = 0.2
Dyslipidemia (%) 41.6 48.8 46.8 1 vs 2, p = 0.2; 1 vs 3, p = 0.8; 2 vs 3, p = 0.4
UFC (%ULN) 8.7 16.5 15.3 1 vs 2, p = 0.04; 1 vs 3, p = 0.08; 2 vs 3, p = 0.8
ACTH (pg/ml) 17.9 ± 16.4 12.9 ± 8.8 9.2 ± 6.8 1 vs 2, p = 0.006; 1 vs 3, p<0.001; 2 vs 3, p = 0.001
N363S% (n) (MAF) 4.8% (11) 0.023 5.4%(5) 0.034 6.6% (6) 0.028 1 vs 2 p = 0.6, 1 vs 3 p = 0.8, 2 vs 3 p = 0.8
BclI % (n) (MAF) 53.2% (122) 0.321 56.5% (52) 0.346 53.3% (48) 0.322 1 vs 2 p = 0.5, 1 vs 3 p = 0.9, 2 vs 3 p = 0.7
ER22/23EK% (n) (MAF) 5.2% (12) 0.026 3.2% (3) 0.021 3.3% (3) 0.017 1 vs 2 p = 0.8, 1 vs 3 p = 0.6, 2 vs 3 p = 0.8
GROUP 1 = Cortisol 1.8 mcg/dL
GROUP 2 = Cortisol>1.9 mcg/dL and3 mcg/dL
GROUP 3 = Cortisol>3 mcg/dL
ULN = Upper limit of normality
Continuous variable are expressed as mean ± SD
To convert conventional units to SI units: for cortisol,multiply by 27.59 to obtain nanomoles per liter; for ACTH, multiply by 0.22 to obtain picomoles per liter.
doi:10.1371/journal.pone.0162437.t002
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A higher prevalence of N363S was observed in hypertensive patients (p = 0.03) and dyslipi-
demic patients (p = 0.06), while we did not find the any association for BclI and ER22/23EK
(Table 4). We did not find any difference in hormonal data betweenwild type subjects and
SNP carriers (Table 5). In univariate analysis, hypertension was associated to older age
(p<0.001), higher BMI (p<0.001), higher cortisol levels after DST (p = 0.005) and presence of
the N363S SNP (p = 0.03) (Table 6). In a multiple regression analysis in the whole series
including age, sex, BMI and the N363S SNP, hypertension was associated to sex and BMI
(p = 0.02 and p<0.01, respectively) while age and N363S SNP were at the limit of the statistical
significance (p = 0.06). The N363S SNP was found to be independently associated with hyper-
tension (p = 0.015) in patients with suppressed cortisol after the 1-mg DST (Table 7). In uni-
variate analysis diabetes was associated with sex (p<0.001), age (p = 0.01) and cortisol levels
after the 1-mg DST (p = 0.02).
Discussion
The first aim of the present study was to assess the frequency of the most studied GR SNPs in
the largest ever published series patients with adrenal incidentalomas.
Table 3. Tabular overview of all NR34C1 variants reported in this paper.
This study MAF in control population
Current
name
Change at DNA and
protein level
refSNP MAF (411
patients)
1000 Genomes EUR (NCBI
Assay ID)
ESP EA ExACNFE
ER23/23EK c.66G>A (p.Glu22Glu) rs6189 2.19% 2.98% (ss1317539291) 2.93% 2.44%
c.68G>A (p.Arg23Lys) rs6190 2.98% (ss1317539290) 2.85% 2.44%
N363S c.1088A>G (p.Asn363Ser) rs56149945 (former rs6195 or
rs356601909)
2.67% 1.79% (ss1317539264) 3.06% 3.19%
BclI c.1184+646C>G (p.?) rs41423247 32.8% 37.97% (ss1317539254) N/A N/A
MAF: Minor Allelic Frequency
1000 Genomes: 1000 genome project Phase3_V1 A global reference for human genetic variation, The 1000 Genomes Project Consortium,Nature 526, 68–
74 (01 October 2015) doi:10.1038/nature15393. (URL: http://www.1000genomes.org/) [07,2016 accessed].
EUR: 1,006 samples of European ancestry
ESP: Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) [07,2016 accessed]
EA: 4,300 European American individuals
ExAC: Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) [07,2016 accessed]
NFE: al least 33,329 European (Non Finnish) subjects
N/A: not available, deep intronic position
doi:10.1371/journal.pone.0162437.t003
Table 4. Correlationbetweenclinical variables and the N363S, Bcl1, ER22/23EKhaplotypes, in patientswith adrenal incidentalomas.
N363S Bcl1 ER22/23EK
Wild type Hetero-
homozygote
p value Wild type Hetero-
homozygote
p value Wild type Hetero-
homozygote
p value
Obesity 72.5% (282/
389)
81.8% (18/22) 0.4 75.7% (143/
189)
70.7% (157/222) 0.3 73.3% (288/
393)
66.7% (12/18) 0.7
Hypertension 63.8% (248/
389)
86.4% (19/22) 0.03 68.3% (129/
189)
62.1% (138/222) 0.2 64.1% (252/
393)
83.3% (15/18) 0.1
Diabetes 25.2% (98/
389)
31.8% (7/22) 0.6 23.8% (45/
189)
27.0% (60/222) 0.5 24.9% (98/
393)
38.9% (7/18) 0.3
Dyslipidaemia 43.2% (168/
389)
63.6% (14/22) 0.06 45.5% (86/
189)
43,2% (96/222) 0.9 44.0% (173/
393)
50% (9/18) 0.8
doi:10.1371/journal.pone.0162437.t004
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Previous studies describe a wide range of prevalence for each SNPs depending on ethnicity.
In the European population, the frequency of hetero/homozygote variant for N363S is esti-
mated to be 3–9%, BclI 35–46% and ER22/23EK 1.6–9% [3, 4, 8, 26]. With the exception for a
non-significant increase of BclI in the patients group (54.7%), we have confirmed previously
published estimates in the general population.
There are studies claiming that some GR variants may have a pathogenetic role on tumour
growth or cortisol production. In a previous study, the C allele of BclI and a minor allele of 9β
were associated with the presence of adrenal incidentaloma[27]. Tzanela and coll. [28] geno-
typed 95 subjects with adrenal incidentaloma for the BclI SNP reporting smaller size of adrenal
nodules in patients carrying the variant. Majnik et al. [29] found that the frequency of the
N363S variant was markedly higher in patients with bilateral incidentalomas, suggesting a pos-
siblepathogenetic role. Trementino and coll.[9] reported a higher prevalence of BclI variants in
patients with Cushing’s syndrome. Szappanos did not confirm these data, demonstrating that
BclI, N363S, ER22/23EK and A3669G (rs6198, c.3833A>G) did not influence the develop-
ment of Cushing’s disease, or adrenal dependent Cushing’s syndrome [1]. Notwithstanding
that the assumption of a pathogenetic role for the GR SNPs is based only on a presumed differ-
ence in their prevalence and is not supported by functional studies, we did not observe any dif-
ference in the SNP prevalence between patients and controls. Discrepancywith some previous
studies may be accounted for the limited sample size of such studies.
The second aim of the study was to assess the genotype to phenotype correlation of BclI,
N363S, and ER22/23EK SNPs of the GR gene in patients with a adrenal incidentalomas.
Table 5. Hormonal features in the different GR polymorphic variant.
N363S Bcl1 ER22/23EK
Wild type
(n = 389)
Hetero-
homozygote
(n = 22)
p
value
Wild type
(n = 189)
Hetero-
homozygote
(n = 222)
p
value
Wild type
(n = 393)
Hetero-
homozygote
(n = 18)
p
value
Cortisol post
DST (mcg/dL)
2.4 ± 2.0 2.5 ± 1.7 0.8 2.5 ± 2.2 2.3 ± 1.9 0.3 2.4 ± 1.9 2.7 ± 2.6 0.5
ACTH (pg/mL) 14.5 ± 13.0 17.7 ± 12.1 0.3 16.3 ± 14.3 14.4 ± 8.1 0.09 14.2 ± 12.1 17.5 ± 14.7 0.3
UFC (%ULN,
n.)
12.8 (50) 9.0 (2) 0.7 9.5 (18) 15.3 (34) 0.1 12.2 (48) 22.2 (4) 0.3
Data are expressed as mean ± SD with the exception of UFC expressed as percentage of patients with levels higher than the upper limit of normality (ULN)
for the reference laboratory.
To convert conventional units to SI units: for cortisol,multiply by 27.59 to obtain nanomoles per liter; for ACTH, multiply by 0.22 to obtain picomoles per liter.
doi:10.1371/journal.pone.0162437.t005
Table 6. Correlationbetween the dependentvariable hypertensionwith clinical, hormonal data andGR polymorphism in univariate analysis.
patients without hypertension N = 143 patients with hypertensionN = 268 p value
sex (female) 59% 65% 0.3
age (years) 53/60/66 57/64/71 <0.001
BMI >25 Kg/m2 64% 81% <0.001
Cortisol after DST (mcg/dL) 1.1/1.7/2.4 1.4/2.0/3.0 0.005
N363S (MAF) 2% (0.01) 7% (0.044) 0.03
BclI (MAF) 58% (0.336) 53% (0.324) 0.3
ER22/23EK 2% (0.01) 6% (0.03) 0.09
Continuous variables are reportedas I quartile/median/ III quartile
To convert conventional units to SI units: for cortisol,multiply by 27.59 to obtain nanomoles per liter
doi:10.1371/journal.pone.0162437.t006
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Adrenal incidentalomas represent an interesting model being characterized by an individual
variability of the cortisol secretory pattern along a continuum from normal cortisol secretion
to cortisol autonomy, in the absence of a specific Cushingoid phenotype. In our series, approxi-
mately 45% of patients showed some degree of cortisol autonomy, heralded by incomplete to
grossly reduced cortisol suppression following the 1-mg DST. The 1-mg DST has been tradi-
tionally used to explore the integrity of the pituitary feedback and is very sensitive for detecting
autonomous cortisol secretion.
The evaluation of the influence of GR polymeric variants on metabolic profile and cardio-
vascular risk has been extensively studied in different clinical settings but results are not homo-
geneous. Attention has been focused on N363S and BclI SNPs, which theoretically confer
enhanced sensitivity to glucocorticoidsgiving a worsenmetabolic profile. However, many stud-
ies did not observe any correlation between the different SNPs and the metabolic profile or car-
diovascular risk [26, 30, 31, 32]. Conflicting results have been also reported for the ER22/23EK
polymorphism in general population. Some studies demonstrated higher cortisol levels after
dexamethasone suppression associated to increased insulin sensitivity, better metabolic profile
and reduced weight, although with a striking gender difference in the SNP effect [3, 8, 33, 34].
Other studies did not confirm these data [26, 35].
In patients with Addison’s disease, a small study on 4 patients carrying the homozygous
BclI polymorphismGG showed a significant BMI increase and a worsen metabolic profile [10].
Ross and coll.[36] showed similar findings, however the analysis was not corrected for the
hydrocortisone dose. A more recent paper by the same authors [37] performedwith a rigorous
statistical evaluation has not demonstrated any influence of the 9β polymorphism on hydro-
cortisone dose and clinical consequences.
Also in patients with Cushing’s syndrome, available data do not support the view that SNPs
variants of GR gene may modulate the effects of cortisol on peripheral tissues. Trementino
et al. [9] reported a higher frequency of the BclI SNP in patients with Cushing’s syndrome
compared to healthy subjects, without any clinical or metabolic consequences in patients carry-
ing the polymorphism.Moreover, SNPs were not associated with fracture risk. Conversely,
Szappanos et al. [1] suggested that BclImay modify the skeletal sensitivity to the glucocorticoid
excess in the 6 patients of the entire series carrying the polymorphic variant.
Scanty data are available in patients with adrenal incidentalomas. Studies have a limited sta-
tistical power, since they usually report on less than 10 patients with the N363S variant, due to
the reduced frequency of the SNP in the general population. The present study represent the
largest series of patients with incidentally discovered adrenal adenoma genotyped for the pres-
ence of BclI, N363S and ER22/23EK SNPs. The clinical characteristics of our patient do not dif-
fer with those previously published, confirming the high frequency of hypertension, diabetes
and cortisol autonomy in such patients. Our results demonstrate that the patients carrying
BclI, N363S and ER22/23EK SNPs do not present any significant hormonal characteristics
compared to the wild-type patients for the GR gene. These results confirm a previous paper by
Morelli showing that the single polymorphic variant did not influence cortisol secretion [14].
Table 7. Multiple regressionanalysis with Firth correction.
AGE SEX BMI N363S
HYPERTENSION (whole series, n = 267) p = 0.06 p = 0.02 p<0.01 p = 0.06
HYPERTENSION (DST <1.8 mcg/dl, n = 137) p = 0.05 p = 0.02 p<0.01 p = 0.015
R2: 0.06; p< 0.01
doi:10.1371/journal.pone.0162437.t007
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As to the issue of whether the GR SNPs may modulate patient presentation, we found that
the N363S polymorphismmay be correlated with the presence of hypertension, at least in the
group of patients who normally suppress cortisol after the 1-mg DST. No phenotype correla-
tion was found with the other studied SNPs. Thus, we confirm and extend results of previous
studies on a small number of patients stratified into two groups by the presence of the sensitiz-
ing SNPs, which were associated with increased prevalence of arterial hypertension and verte-
bral fractures. It is possible to speculate that the relationship between the N363S SNP and the
risk of hypertension may be masked when a minimal degree of cortisol excess becomes
apparent.
We should acknowledge the limits of a retrospective,multicentre evaluation and the lack of
data on bone metabolism and vertebral fracture. However, the patients were studied in referral
centres for adrenal disease where pre-specified specific protocols have been set. We are also
aware that the sensitivity of the glucocorticoid receptor is influencednot only by the examined
polymorphisms, but also from other point mutations, including hGRαT556I (inactivating
mutation of GR, causes Chrousos syndrome), recently reported in a case of adrenal incidenta-
loma [38]. Strengths of the study are the sample size, which is larger than the sum of all previ-
ous published series, and the strict patient categorization.
Conclusion
In conclusion, the frequency of the different polymorphic GR gene variants does not differ
between patients and controls, and this militates against a possible pathogenetic role of the GR
SNPs in development of adrenal adenomas. The most interesting result is the association of the
N363S SNP with arterial hypertension, which should confer risk susceptibility in patients with
non-functioning adrenal adenomas. However, our results demonstrate that the impact of any
single SNP on disease expression is limited and their analysis does not provide additional data
that may be exploited for patient management.
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